H. M. Esther van Egmond

Effective Treatment of Refractory CMV Reactivation After Allogeneic Stem Cell Transplantation With In Vitro-generated CMV pp65-specific CD8+ T-cell Lines

Pauline Meij, Inge Jedema, Maarten L. Zandvliet et al. · Journal of Immunotherapy · 2012 · 53 citations

Life Sciences, Immunology, Infectious Diseases +15

Functional Analysis of Killer Ig-Like Receptor-Expressing Cytomegalovirus-Specific CD8+ T Cells

Lars T. van der Veken, María Díez‐Campelo, Menno A. W. G. van der Hoorn et al. · The Journal of Immunology · 2009 · 45 citations · Full text

Life Sciences, Cell Biology, Immunology +15

Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application

Marieke Griffioen, H. M. Esther van Egmond, Helen E. Barnby-Porritt et al. · Haematologica · 2008 · 41 citations · Full text

Life Sciences, Biotechnology, Immunology +17

Up-regulated expression in nonhematopoietic tissues of the BCL2A1-derived minor histocompatibility antigens in response to inflammatory cytokines: relevance for allogeneic immunotherapy of leukemia

Freke M. Kloosterboer, Simone A.P. van Luxemburg-Heijs, Ronald A van Soest et al. · Blood · 2005 · 20 citations · Full text

Life Sciences, Immunology, Oncology +11

Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors

Floris C. Loeff, H. M. Esther van Egmond, Bart Nijmeijer et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2017 · 17 citations

Life Sciences, Immunology, Oncology +17